PharmaCircle Blog Product Exclusivity, Drug Delivery Enabled/Enhanced Products (DDEP 1996-2010) - Chapter 9

All pharmaceutical products, some sooner than others, are subject to direct competition. This can take the form of Functional Equivalents, products that are different in their active or dosage form, but are targeted to a similar indication and patient population. Think PEGIntron and Pegasys for Hepatitis C, similar indications with basically identical actives and dosage forms. And there [...]